TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27694157

Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m2 intravenously or 2.3 mg/m2 orally, daily for 5 days for 4 cycles)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Linsitinib (150 mg orally twice daily until progression)
Number of subjects: 37
Study: 26627881

Group type: EXPERIMENTAL
Intervention: POC-Troponin
Number of subjects: 601

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 601
Study: 23553863

Group type: EXPERIMENTAL
Intervention: valsartan (VAL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 20603462

Group type: EXPERIMENTAL
Intervention: Usual care with coaching
Number of subjects: 362

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 362
Study: 19086108

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with oestradiol and noretisterone acetate, vitamin D3 and calcium
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vitamin D3 and calcium alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 88
Study: 16647414

Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Enhanced Standard of Care (ESC)
Number of subjects: 49
Study: 12600843

Group type: EXPERIMENTAL
Intervention: 10 g high-performance inulin/d
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 8
Study: 11005114

Group type: EXPERIMENTAL
Intervention: Ultrasound examination at the 18th and 32nd week of pregnancy in addition to routine antenatal care
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Standard antenatal care with referral for ultrasound on clinical indication
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 1628
Study: 9526603

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8407216

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 25/6.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 50/12.5 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Tums)
Number of subjects: 20
Study: 3940504

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (300 mg orally) with zinc sulfate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (30 mL orally) with zinc sulfate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zinc sulfate alone
Number of subjects: 12
Study: 29630132

Group type: EXPERIMENTAL
Intervention: Sevoflurane combined with remifentanil
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol combined with remifentanil
Number of subjects: 150
Study: 27602929

Group type: EXPERIMENTAL
Intervention: Self-prepared, 1-day, low-residue diets with a same-day 2.0-L single-dose of polyethylene glycol (Group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Prepackaged low-residue diets plus 2.0 L of polyethylene glycol (Group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Prepackaged low-residue diets plus 1.5 L of polyethylene glycol (Group C)
Number of subjects: 180
Study: 24258020

Group type: EXPERIMENTAL
Intervention: Microfracture/Biomembrane
Number of subjects: 64

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 64
Study: 23506436

Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (10 g · kgBM(‐1) of ice slurry < 1°C)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Room temperature fluid (32‐34°C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Room temperature fluid
Number of subjects: 9
Study: 20019315

Group type: COMPARATOR
Intervention: Online untailored program (arm 1)
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Tailored behavioral intervention (arm 2)
Number of subjects: 2540

Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention plus motivational interviewing‐based counseling via e‐mail (arm 3)
Number of subjects: 2540
Study: 18155205

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 65

Group type: COMPARATOR
Intervention: ERCP
Number of subjects: 65
Study: 16708558

Group type: EXPERIMENTAL
Intervention: Anteroseptal myocardial infarction (aMI) group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction (iMI) group
Number of subjects: 68
Study: 12693746

Group type: EXPERIMENTAL
Intervention: Intervention program consisting of 6 sessions of 30 minutes each over 4 weeks to teach discrimination, identification, expression, and application of facial expression cues.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 30
Study: 11040014

Group type: EXPERIMENTAL
Intervention: Elective stent implantation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Crossover from balloon angioplasty to stenting
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups (stent and balloon angioplasty)
Number of subjects: 300
Study: 9275430

Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes (TIL) and chemotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 25
Study: 1739568

Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 32
Study: 6730874

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0
Study: 31615471

Group type: COMPARATOR
Intervention: fTcSC
Number of subjects: 116
Study: 29995356

Group type: EXPERIMENTAL
Intervention: Withania somnifera extract (WSE) 1,000 mg/d
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27580669

Group type: EXPERIMENTAL
Intervention: Physiotherapy and Occupational Therapy (PT and OT) NHS services, n=381
Number of subjects: 762

Group type: COMPARATOR
Intervention: No therapy, n=381
Number of subjects: 762
Study: 24526592

Group type: EXPERIMENTAL
Intervention: Light-weight mesh (LWM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heavy-weight mesh (HWM)
Number of subjects: 0
Study: 21324655

Group type: EXPERIMENTAL
Intervention: rTMS to the VMPFC
Number of subjects: 13

Group type: COMPARATOR
Intervention: sham‐rTMS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rTMS to the vertex
Number of subjects: 13
Study: 20142595

Group type: EXPERIMENTAL
Intervention: Single subcutaneous pegfilgrastim injection (100 microg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Daily subcutaneous filgrastim administration (5 microg/kg)
Number of subjects: 44
Study: 16936584

Group type: EXPERIMENTAL
Intervention: Unrestricted weightbearing combined with intensive physiotherapy from the first day after surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Partial weightbearing and a conservative training regimen for the first 3 months after surgery
Number of subjects: 29
Study: 16563271

Group type: EXPERIMENTAL
Intervention: Xuezhikang (0.6 g, Bid)
Number of subjects: 591
Study: 12372764

Group type: EXPERIMENTAL
Intervention: DDAVP + low-calcium diet (approximately 500 mg/day) for 3-6 months in hypercalciuric patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DDAVP for 3-6 months in all patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-calcium diet (approximately 500 mg/day) for 3-6 months in hypercalciuric patients
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: DDAVP for 3-6 months in normocalciuric children
Number of subjects: 46
Study: 10197860

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control subjects (age-matched healthy subjects)
Number of subjects: 111
Study: 8849179

Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg
Number of subjects: 120
Study: 1431364

Group type: EXPERIMENTAL
Intervention: Cefepime (CFPM) 1.0 g twice daily for 14 days
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ceftazidime (CAZ) 1.0 g twice daily for 14 days
Number of subjects: 183
Study: 4005394

Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefadroxil 500 mg
Number of subjects: 12
Study: 31100296

Group type: EXPERIMENTAL
Intervention: 20 minutes of perceived exertion-based high-intensity cycling exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 32
Study: 29851567

Group type: EXPERIMENTAL
Intervention: Elder mistreatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Family environment with psychological and physical abuse
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Social environment characterized by loneliness
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mistreated older adults
Number of subjects: 400
Study: 27142231

Group type: EXPERIMENTAL
Intervention: Spiritually framed breast cancer screening message
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional breast cancer screening message
Number of subjects: 200
Study: 24803174

Group type: EXPERIMENTAL
Intervention: Training of phonics, reading comprehension strategies, and reading speed
Number of subjects: 112
Study: 21755578

Group type: EXPERIMENTAL
Intervention: Group A (three walks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B (two walks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group C (one walk)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 30
Study: 20921836

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (BTX-A) injection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control drug (NaCl 0.9% or bupivacaine 0.25%)
Number of subjects: 27
Study: 18522664

Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 805

Group type: COMPARATOR
Intervention: UC
Number of subjects: 805
Study: 16083067

Group type: EXPERIMENTAL
Intervention: High dose MNZ (2 g daily for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg N‐9 vaginal suppository daily for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional MNZ dose (1 g daily for 7 days) plus 100 mg N‐9 suppository for 7 days
Number of subjects: 30
Study: 11840225

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9597063

Group type: EXPERIMENTAL
Intervention: CL-CANE
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CL-CANE+
Number of subjects: 24

Group type: COMPARATOR
Intervention: IL-CANE
Number of subjects: 24
Study: 9316695

Group type: EXPERIMENTAL
Intervention: L-DOPA (LD) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmedicated state
Number of subjects: 0
Study: 3354990

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg four times a day for 7 doses)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30844990

Group type: EXPERIMENTAL
Intervention: Active recovery (AR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive recovery (PR)
Number of subjects: 25
Study: 29327644

Group type: EXPERIMENTAL
Intervention: PREHAB+ (once weekly supervised prehabilitation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: REHAB (standard rehabilitation)
Number of subjects: 80
Study: 27064347

Group type: EXPERIMENTAL
Intervention: Body Psychotherapy/Dance Movement Therapy (BPT/DMT) - 20 sessions
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 68
Study: 24300949

Group type: EXPERIMENTAL
Intervention: Memory Self-efficacy (MSE) training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Peer support group
Number of subjects: 153
Study: 22938573

Group type: EXPERIMENTAL
Intervention: 6 mm implants
Number of subjects: 95

Group type: COMPARATOR
Intervention: 11 mm implants
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study: 20413999

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 20031783

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus optimal medical therapy
Number of subjects: 2287

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2287

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2287
Study: 16341846

Group type: EXPERIMENTAL
Intervention: Tiagabine (open-label for 12 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tiagabine (double-blind phase)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (double-blind phase)
Number of subjects: 29
Study: 14604881

Group type: EXPERIMENTAL
Intervention: Pelvic examination training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Educational literature (Control)
Number of subjects: 72
Study: 10944126

Group type: EXPERIMENTAL
Intervention: LV5FU2 plus oxaliplatin (200 mg/m2/d leucovorin, 400 mg/m2/d bolus 5FU, 600 mg/m2/d infusional 5FU for 2 days every 2 weeks, plus 85 mg/m2 oxaliplatin on day 1)
Number of subjects: 420

Group type: COMPARATOR
Intervention: LV5FU2 alone (200 mg/m2/d leucovorin, 400 mg/m2/d bolus 5FU, 600 mg/m2/d infusional 5FU for 2 days every 2 weeks)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: LV5FU2 plus oxaliplatin
Number of subjects: 420

Group type: COMPARATOR
Intervention: LV5FU2 alone
Number of subjects: 420
Study: 8746336

Group type: EXPERIMENTAL
Intervention: Topical calcitriol (1.5 micrograms per day, 15 micrograms/g of Vaseline)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Topical calcitriol ointment (15 micrograms/g Vaseline) applied to all lesions (up to 10 g, 150 micrograms calcitriol)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Vaseline (placebo)
Number of subjects: 84
Study: 8227844

Group type: EXPERIMENTAL
Intervention: Basic cycle length of 400 ms with up to at least four extrastimuli
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Basic cycle length of 600 ms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sinus rhythm
Number of subjects: 28

Group type: COMPARATOR
Intervention: Basic cycle lengths of 400 ms and 600 ms
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Basic cycle length of 400 ms
Number of subjects: 28
Study: 3512021

Group type: EXPERIMENTAL
Intervention: Controlled environment unit
Number of subjects: 60

Group type: COMPARATOR
Intervention: Plaster dressings
Number of subjects: 60
Study: 29975091

Group type: EXPERIMENTAL
Intervention: Subjective state of mind
Number of subjects: 0

Group type: COMPARATOR
Intervention: Objective state of mind
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laboratory experiment (objective state)
Number of subjects: 0
Study: 27206539

Group type: EXPERIMENTAL
Intervention: IVR‐BI
Number of subjects: 1567

Group type: COMPARATOR
Intervention: Usual care (no IVR‐BI)
Number of subjects: 1567
Study: 25037455

Group type: EXPERIMENTAL
Intervention: Resilience-based intervention in intervention schools
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 22019502

Group type: EXPERIMENTAL
Intervention: Athlete-modified dissonance prevention
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Healthy weight intervention (AM-HWI)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 157
Study: 20510549

Group type: EXPERIMENTAL
Intervention: Heroin Assisted Treatment (HAT)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Optimized Methadone Maintenance Treatment (MMT)
Number of subjects: 251
Study: 18677239

Group type: EXPERIMENTAL
Intervention: 0.3% Carbomer 934
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate (SH)
Number of subjects: 65
Study: 16685988

Group type: EXPERIMENTAL
Intervention: Multiple electrophysiological atlases used for DBS target point prediction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single reference volume (not explicitly mentioned but implied as a comparison)
Number of subjects: 0
Study: 12765436

Group type: EXPERIMENTAL
Intervention: Computer-animation programs (candles and balloon)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Training with a program for a short period of time before the formal lung-function test
Number of subjects: 88
Study: 10337847

Group type: EXPERIMENTAL
Intervention: Nurse counseling
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 77
Study: 8543957

Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manufacturer and brand of L-tryptophan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 1791086

Group type: EXPERIMENTAL
Intervention: Single-dose verapamil (120 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Seven-doses of verapamil (120 mg thrice daily)
Number of subjects: 10
Study: 6780258

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) treatment for 48 hours
Number of subjects: 46
Study: 30872114

Group type: EXPERIMENTAL
Intervention: Mail-in questionnaire/live telephone interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated telephone/interactive voice recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based computer Kiosk technologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-home instruments
Number of subjects: 0
Study: 27873477

Group type: EXPERIMENTAL
Intervention: Telemedically supported case management
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard aftercare
Number of subjects: 46
Study: 25623343

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I), 8 sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Behavioral desensitization (active placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 100
Study: 24140142

Group type: EXPERIMENTAL
Intervention: Intra-articular injection
Number of subjects: 101

Group type: COMPARATOR
Intervention: Periarticular injection
Number of subjects: 101
Study: 22171804

Group type: EXPERIMENTAL
Intervention: Disease management programme (n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Care as usual (n = 80)
Number of subjects: 160
Study: 18323556

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 44

Group type: COMPARATOR
Intervention: PEG interferon alpha-2b
Number of subjects: 44
Study: 16685556

Group type: EXPERIMENTAL
Intervention: Modified Hardinge approach with limited incision (average 10 cm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard incision (not directly compared in this study)
Number of subjects: 0
Study: 12582402

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Number of subjects: 1
Study: 10783015

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg of retinol as retinyl palmitate) during acute diarrhea
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg of retinol as retinyl palmitate) after resolution of diarrhea
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation during acute diarrhea
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation after resolution of diarrhea
Number of subjects: 68

Group type: COMPARATOR
Intervention: Vitamin A supplementation (both during acute diarrhea and after resolution)
Number of subjects: 68
Study: 8803503

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g, administered 2 hours before and after 20 km of the marathon)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 7
Study: 1615614

Group type: EXPERIMENTAL
Intervention: Doxorubicin (20 mg/m2 body surface area)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 111
Study: 6235140

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg twice daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1 g/wk intramuscularly
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Combination therapy (TAM and MPA)
Number of subjects: 93
Study: 31810057

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - heel drop exercises for 13 weeks including 1 week of control, 8 weeks of eccentric training, and 4 weeks of detraining.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG) - no muscular training.
Number of subjects: 45
Study: 29580754

Group type: COMPARATOR
Intervention: SIT + PA
Number of subjects: 36

Group type: COMPARATOR
Intervention: RAB
Number of subjects: 36

Group type: COMPARATOR
Intervention: RAB + PA
Number of subjects: 36
Study: 28214943

Group type: EXPERIMENTAL
Intervention: Mesh fixation group (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mesh non-fixation group (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 26292721

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring
Number of subjects: 52

Group type: COMPARATOR
Intervention: Blinded continuous glucose monitoring
Number of subjects: 52
Study: 23323964

Group type: EXPERIMENTAL
Intervention: Removable mandibular retractor (RMR)
Number of subjects: 67
Study: 21663656

Group type: EXPERIMENTAL
Intervention: Indoor Residual Spraying (IRS with DDT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Long-Lasting Insecticidal Nets (LLINs)
Number of subjects: 1000
Study: 18962989

Group type: EXPERIMENTAL
Intervention: EPA 2 g/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16622734

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (severe, moderate, mild)
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (severe, moderate)
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Usual biochemical parameters (calcium, phosphate, Alk Ph)
Number of subjects: 1210
Study: 14507300

Group type: EXPERIMENTAL
Intervention: Female elite athletes
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Athletes with eating disorders (ED)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Non-ED athletes
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Athletes
Number of subjects: 1440